Login to Your Account



Asterias non-spurious: Bid proves merit in spine injury

By Randy Osborne
Staff Writer

Tuesday, January 24, 2017

"Everything we're seeing now leads us to believe that this is going to be a sustainable effect," Asterias Biotherapeutics Inc. CEO Steve Cartt told BioWorld Today, talking about positive results from the ongoing SCiStar phase I/IIa trial with AST-OPC1 in patients rated to have complete cervical spinal cord injury.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription